Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2017 · 10-K
Revenue$88.44M$88.44M+41.8% vs Q4 2016 Net Income$13.66M$13.66M−4.6% vs Q4 2016 EPS Diluted$0.26$0.26±0.0% vs Q4 2016 Operating Income$34,344,000+110.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$35,579,000+44.4% Margins · derivedOperating margin38.8%+12.7 pt vs Q4 2016
Net margin15.4%−7.5 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 1, 2018 · 60 d after period end